You are here
Poor patient adherence is fueling keen interest in the development of drugs for glaucoma management. Several long-acting formulations of existing medications are in the early stages of development, as are new therapeutic classes such as guanylate cyclase activators.
Therapeutic options in development for the treatment of Crohn’s disease represent a broad range of approaches to this complex disease. This active pipeline contains a combination of both small-molecule entities and targeted monoclonal antibodies.
Despite failures in late-phase trials, the pipeline of medications for Alzheimer’s disease is robust as companies hope to be the first to bring an effective therapy to market. We review several investigational agents in late-stage development.
Upcoming antibacterial agents in the pipeline appear promising, but it is difficult to predict their long-term durability. This article focuses on investigational agents that target resistant gram-negative organisms commonly found in the health care setting.
The landscape of migraine therapy is set to change with the introduction of new classes of medications aimed at providing options for patients who have not responded to previous therapies. However, the pricing of the new agents will likely be a key determinant in the extent of their use in clinical practice.
We review the immunomodulatory agents in development for systemic lupus erythematosus, a relatively uncommon disorder affecting women of childbearing age.
We present immunotherapies, biosimilars, and molecular-targeted agents in late-stage development for patients with advanced colorectal cancer.
We present several novel drugs in development for enhancing cognition, treating negative symptoms, and providing improved options for treatment-resistant patients. Drug makers aim to enhance safety profiles and increase patient compliance to therapy.
Despite the many medications already available, patients with heart failure often have disease exacerbations, reduced quality of life, and increased mortality, highlighting the need for new treatment approaches. We explore drugs currently in development.
Analysts have identified several unmet needs in the HIV therapy marketplace. We present the promising candidates in late-stage clinical development or FDA review.